Given the tumor immunology, PD-1 mainly inhibits T cell activation in TM at later stages of tumor growth, whereas signaling via CTLA-4 regulates T cell activation in the early stage of T cell response in the lymph nodes (LNs) (147). Here, CTLA4 is linked to neoplasm.